We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

RAS Quantification in Patients With Aliskiren or Candesartan (RASQAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01827202
Recruitment Status : Completed
First Posted : April 9, 2013
Last Update Posted : March 16, 2016
Information provided by (Responsible Party):
Marcus Saemann, Medical University of Vienna

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Primary Completion Date : February 2016
  Study Completion Date : February 2016